Atom Grants
Discover
  • Dashboard
  • Search
  • Deep Research
  • Favorites
  • Projects

    MSCRF Validation Program

    MSCRF Validation Program supports Maryland academic researchers in validating human stem cell technologies for commercial feasibility, helping move research toward products that address unmet medical needs.

    OverviewSimilar Grants
    OverviewSimilar Grants

    Funder: Maryland Technology Development Corporation (TEDCO)

    Due Dates: January 20, 2027, at 5:00 p.m. EST (Application) | Week of April 4, 2027 (Peer review and presentation) | May 2027 (Award announcement)

    Funding Amounts: Up to $250,000 for up to 2 years; up to $350,000 total with Second-tier Funding

    Summary: Supports commercial validation of Maryland academic human stem cell technologies addressing unmet medical needs.

    Key Information: Technologies must have university/research institute-owned patent protection and cannot already be optioned or licensed commercially.


    Description

    The Maryland Stem Cell Research Fund (MSCRF), administered by TEDCO, supports the transition of promising stem cell technologies from universities and research laboratories into commercial products and services. The Validation Program funds research involving human stem cells, derivatives such as extracellular vesicles and secretome, and technologies that enable or support stem cells. Its focus is validating existing findings for commercial feasibility, rather than discovery research.

    The program combines technology validation, market assessment, and pathways to licensing to address unmet medical needs. It also encourages collaboration across academic schools, departments, and institutions, and between Maryland’s public and private sectors. Supplementary Second-tier Funding supports technology development through collaboration between academic institutions and Maryland businesses.


    Atom

    See the full grant listing

    Sign in to view full eligibility details, sources, similar grants, and AI-powered analysis.